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Growingevidence suggeststhatacomplex relationshipexists between thecentral nervoussystemandperipheral organsinvolvedin
energy homeostasis.It consists in the balance between food intake and energy expenditure and includes the regulation of nutrient
levels in storage organs, as well as in blood, in particular blood glucose. Therefore, food intake, energy expenditure, and glucose
homeostasisarestrictlyconnectedtoeachother.Severalhormones,suchasleptin,adiponectin,resistin,andghrelin,areinvolvedin
this complex regulation. These hormones play a role in the regulation of glucose metabolism and are involved in the development
of obesity, diabetes, and metabolic syndrome. Recently, their presence in breast milk has been detected, suggesting that they may
be involved in the regulation of growth in early infancy and could inﬂuence the programming of energy balance later in life. This
paper focuses on hormones present in breast milk and their role in glucose homeostasis.
1.Introduction
It is well known from researches and literature data that
food intake, energy expenditure, and glucose homeostasis
are regulated by hypothalamic areas in which a variety of
peripheral signals converge [1]. In conditions of excessive
energy storage or nutrient abundance, speciﬁc hypothalamic
areas reduce food intake, increase energy expenditure, and
diminish endogenous glucose production. Therefore, in
response to a reduction in energy stores or circulating
nutrients, the brain promotes a positive energy balance to
restore and maintain energy and glucose homeostasis.
Insulin and leptin, which act as adiposity signals, play a
pivotal role in the central regulation of energy homeostasis
[2]. Both hormones circulate at levels proportional to body
fat and regulate food intake and energy expenditure by inter-
acting with their respective receptors[3].They also inﬂuence
glucose metabolism, acting at a peripheral and central level
[4]. It is now recognized that, as well as leptin, adipose tissue
produces other bioactive peptides called adipokines, which
both inﬂuence autocrine and paracrine function of blood-
stream and exert an endocrine function by their release in
bloodstream [5]. Adiponectin has been hypothesized to act
as a link between accumulated fat mass and altered insulin
sensitivity even though the contribution to the development
of insulin resistance is complex and not fully understood.
Particularly, it has been observed that adiponectin increases
fatty acid (FA) oxidation and decreases triglyceride storage
in skeletal muscle, which may explain, in part, the insulin-
sensitizing eﬀect of this cytokine [6]. Conversely, resistin has
been implicated in impairing insulin sensitivity in rodents
[7], while its role in the development of insulin resistance
in humans is still controversial [8]. The mechanism involved
seems to be the impairing of glucose uptake in skeletal
muscle, while there is little information regarding the eﬀect
of resistin on skeletal muscle FA metabolism [9]. As basal
levelsofinsulinandleptinarewidelyacceptedtobeadiposity
signals, also ghrelin has been hypothesized to have the same
role. An association between basal ghrelin levels and levels of
adiposity has been postulated, and the presence of receptors
of this hormone regulating energy homeostasis in neural
circuits has been demonstrated [1]. Also ghrelin is involved
in glucose metabolism, and there is a relationship between
ghrelin and insulin levels.
Early nutrition could exert both short- and long-term
eﬀects on the programming of metabolic development and2 International Journal of Pediatrics
growth. In this contest, it is interesting to know that breast
milk (BM) contains hormones such as leptin, adiponectin,
resistin, and ghrelin, which play a role in energy balance
regulation and glucose homeostasis. These hormones may
be involved in the regulation of growth and development
in the neonatal age and infancy and could inﬂuence the
programming of energy balance regulation in childhood and
adulthood.
Further diet-related diﬀerences during infancy in serum
levelsoffactorsinvolvedin energymetabolismmight explain
anthropometric diﬀerences and diﬀerences in dietary habits
between breast-fed (BF) and formula-fed (FF) infants also
later in life and may thus have long-term health conse-
quences. In this context, the recent ﬁnding of higher leptin
levels and lower ghrelin levels in BF infants than in FF ones
suggests that diﬀerences in hormonal values together with
diﬀerent protein intake could account for the diﬀerences in
growth between BF and FF infants both during infancy and
later in life [10].
Here, we review data related to hormones contained in
mother’s milk and their role in the regulation of glucose
homeostasis (Table 1).
2.Leptin
Leptin, the product of the obesity (ob) gene, is a 16kDa pep-
tide that is primarily produced by white adipose tissue along
withotheradipokines[11].Extra-adiposeleptinsynthesizing
sites are hypothalamus, pituitary, skeletal muscle, stomach,
liver, and placenta [12]. Moreover, leptin is present in
human milk, produced and secreted by mammary epithelial
cells in milk fat globules [13]. Recent data about leptin
concentration in BM showed variations, mainly according to
the BM fractions and thesample treatments used, with mean
values ranging from 0.2 to 73.22ng/mL [14].
Circulating leptin concentration has been reported to
correlate closely with body mass index (BMI) and the total
amount of body fat [15]. Leptin is secreted in a pulsatile
manner and has signiﬁcant plasma diurnal variation, with
higher levels in the evening and early morning hours [16].
The normal range for plasma leptin in healthy adult
subjects is 3–5ng/mL, while concentrations reported in
obese humans are much higher, in the range of 8–90ng/mL
[17]. In a study conducted on healthy infants, mean serum
leptin concentration was 3.35ng/mL [10].
Leptin’s main function consists in signalling to the brain
how much fat is being stored and to regulate food intake. In
the arcuate nucleus of hypothalamus, leptin stimulates the
secretion of anorexigenic peptides, such as proopiomelano-
cortin (POMC) and cocaine- and amphetamine-regulated
transcript (CART), and inhibits the secretion of orexigenic
peptides, such as neuropeptide Y (NPY) and the agouti
gene-related protein (AgRP) [18]. In addition to its central
eﬀects,leptininteractswithperipheral tissues includingskel-
etal muscle, liver, and pancreas, modulating glucose and
fat metabolism [6]. Leptin mediates its eﬀects by binding
to speciﬁc receptors (ObRs) expressed in the brain and
in peripheral tissues. The binding of leptin to its receptor
activates several signal transduction pathways, including
Janus kinase signal transducer and activator of transcription
3 (JAK-STAT3), which is important for the regulation of
energy homeostasis [19], and phosphatidylinositol 3-kinase
(PI3K), which is important for the regulation of both
food intake and glucose homeostasis [20]. In fact, recent
evidence underlines that, besides its peripheral action, leptin
plays also an important role in the hypothalamic control
of glucose metabolism. For this action the activation of
the insulin receptor substrate-2 (IRS-2) and hypothalamic
PI3K pathway, which is the major intracellular mediator
of insulin action, is required [21]. Therefore, the arcuate
nucleus of hypothalamus is an important site mediating the
eﬀect of leptin in the control of glucose metabolism, for
its neuronal subsets that can control food intake, energy
expenditure, and insulin sensitivity. At this level, leptin and
insulin inhibit NPY/AgRPneurons and activate POMC ones.
Both neuronal subsets project to paraventricular nucleus
(PVN) and lateral hypothalamic area (LHA) and from these
to other hindbrain areas such as nucleus of the solitary
tract (NTS), generating a vagal signal to the liver to regulate
hepatic glucose production [1].
Leptin may also increase energy expenditure, rising sym-
pathetic nerve activity and activating brown adipose tissue
thermogenesis; however, these eﬀects have been conﬁrmed
only in mice [22].
2.1. Role of Leptin on Glucose Homeostasis and Insulin Action.
Studies in animals and humans show that leptin plays a
pivotal role in the regulation of glucose homeostasis. In lean
rats, systemic or central leptin infusion leads to a rapid
redistribution of hepatic glucose ﬂuxes with a stimulation
of gluconeogenesis and inhibition of glycogenolysis [23].
Experimental studies in rats show that leptin can reduce
insulin secretion [24, 25]. Also in studies on human pan-
creatic beta cells, an inhibitory eﬀect of leptin on insulin
secretion was detected, while insulin promotes leptin secre-
tion [26].
Leptin improves insulin sensitivity reducing intracellular
lipid levels in skeletal muscle, liver, and pancreatic beta
cells. In muscle, insulin sensitization is achieved through
malonyl CoA inhibition, which increases transport of FA
into mitochondria for beta oxidation. These changes are
partially mediated by central sympathetic activation of
adrenergic receptors [27].
States of congenital leptin deﬁciency because of muta-
tions of the leptin gene have been associated with severe obe-
sity, glucose intolerance, diabetes, and insulin resistance in
humans. Leptin treatment in humans with congenital leptin
deﬁciency has been shown to improve glycemic control and
hyperinsulinemia [28]. Similarly, lipodystrophic syndromes,
with complete or partial absence of subcutaneous adipose
tissue, have been associated with low leptin concentrations
and diabetes. Leptin administration in replacement doses
in HIV-positive patients with partial lipoatrophy improved
glycemia, dyslipidemia, and insulin resistance [29].
Oral administration of thishormone at dosesclose to the
physiological concentration in milk reduced food intake inInternational Journal of Pediatrics 3
Table 1: Breast milk (BM) hormones and their action on glucose homeostasis.
BM levels (range or mean value) Blood glucose Insulin secretion Insulin action
Leptin 0.2–73.22ng/mL Reduces Inhibits Increases
Adiponectin 4–88ng/mL Reduces Inhibits Increases
Resistin 1745pg/mL Increases ? Reduces
Ghrelin 97.3–3250pg/mL Increases Inhibits Reduces









n e w b o r nr a t sa n dw a sa b s o r b e db yt h er a t ’ ss t o m a c hd u r i n g
neonatal development thereby triggering downregulation of
endogenous leptin production [30]. In a study of rat pups
monitoredinto adulthood,animalsgivenphysiologicaldoses
of oral leptin during lactation had lower body weight and fat
content than untreated animals, which suggests that leptin
could have long-term eﬀects on body weight regulation [31].
More recently, leptin-treated animals were found to have
lowerbody weight inadulthood,toeatfewercalories, tohave
higher insulin sensitivity, and to show a lower preference for
fat-rich food than their controls [32]. Farooqi et al. observed
that administration of exogenous leptin to leptin-deﬁcient
children resulted in a remarkable decrease in their energy
intake and a dramatic loss of fat mass while maintaining
lean body mass [33]. Furthermore, it has been observed
that the administration of exogenous leptin fails to reduce
adiposity signiﬁcantly in most cases of human obesity that
are characterized by increased adipocyte leptin content and
high circulating leptin levels, reﬂecting a state of leptin
resistance [34].
The concept of “leptin resistance” was introduced when
increased adipose leptin production was observed in obese
individuals, who were not leptin deﬁcient; the failure of
high leptin levels to suppress feeding and decrease body
weight or adiposity to prevent or mitigate obesity suggests
a relative resistance to the catabolic eﬀects of leptin action
in obesity [35]. Therefore, obese subjects show high leptin
levels, while congenital leptin deﬁciency is associated with
obesity (Table 2).
2.2. Leptin and Glucose Homeostasis in Newborns and Infants.
Many experimental data suggest that leptin role in the
regulation of food intake and energy homeostasis begins
in early life, when this hormone also controls fetal growth
and development [36]. It has been also observed that leptin
is an essential factor for the development of hypothalamic
pathways involved in the regulation of energy balance and
that this activity is restricted to a neonatal critical period.
Leptin is an intrinsic part of the maturation process of
pathways involved in appetite regulation; in mice, there is a
surge in leptin soon after birth where thetiming is criticalfor
the correct development of the pathways [37].
At birth, serum leptin concentrations seem to be related
to the amount of body adipose tissue. Positive correlations
between cord blood leptin levels, birth weight, BMI, insulin
and insulin-glucose ratio have been reported for full-term
infants andpretermones[38].Inappropriate-for-gestational
age (AGA) term infants, mean concentration of leptin was
4.01 ± 3.5ng/mL, lower than thatin large-for-gestational age
(LGA) term infants in which cord leptin concentration was
7.3 ± 3.8ng/mL. Preterm infants had a mean leptin level of
1.8 ± 0.97ng/mL, and the concentration observed in IUGR
infants was 6.5 ± 3.9ng/mL [39].
Cord blood leptin concentration has been observed to
be related to rates of intrauterine growth, suggesting a
possible role of leptin in promoting fetus growth: small-for-
gestational age (SGA) neonates have lower leptin levels at
birth (3.3 ± 0.5μg/L) than AGA infants (14.5 ± 2.8μg/L),
andLGAneonateshavehigherleptinlevelsthanotherinfants
(35.7 ± 8.0μg/L) [40].
A trend for higher leptin levels in LGA infants of diabetic
mothers than in LGA ones of nondiabetic mothers was
observed. Both groups of LGA infants showed lower glucose
levels [41].
Cord blood leptin seems to be a predictor of weight gain
also in later life; in fact, lower cord blood leptin levels have
been observed to be associated with smaller size at birth but
more pronounced weight gain in the ﬁrst 6 months of life
and higher BMI at 3 years of age [42].
As concerns infants, higher serum leptin concentrations
were detected during the ﬁrst months of life in breast-fed
infants (5.1 ± 3.6ng/mL) compared to those who were fed
with formula (4.2 ± 4.9ng/mL) [43].
3.Adiponectin
Adiponectin, discovered in 1995, is the most abundant
adipose-speciﬁc protein, and its multiple functions have
started to emerge in recent years [44]. In adults, plasma
adiponectin concentration ranges from 0.5 to 30μg/mL,
1000-foldhigherthantheconcentrationsofotherhormones,
such as insulin or leptin.
A reduction in adiponectin expression has been asso-
ciated with insulin resistance, whereas administration of
adiponectin is accompanied by an increase in insulin
sensitivity. Adiponectin production is regulated by the4 International Journal of Pediatrics
peroxisomal proliferator-activated receptor-γ (PPAR-γ), a
nuclear receptor whose expression in liver and muscle seems
to be important in the mediation of obesity-related insulin
resistance [45]. Adiponectin binds to two diﬀerent receptors:
AdipoR1 is abundantly expressed in skeletal muscle, while
AdipoR2 is predominantly expressed in the liver. It has been
observed that suppression of both AdipoR1 and AdipoR2
expression abolishes adiponectin binding and decreases
PPARα ligand activity, fatty acid oxidation, and glucose
uptake [46].
Adiponectin exists in plasma in oligomeric complexes,
consisting of trimers (low molecular weight), hexamers
(medium molecular weight), and large multimers of 12–18
subunits (high molecular weight (HMW)) [47]. HMW
adiponectin mediates insulin sensitization in peripheral
tissues and seems to be the most biologically active form
of adiponectin in terms of glucose homeostasis [48]. HMW
adiponectin seems to be a better predictor of insulin
resistance than total adiponectin [49]; in particular, the ratio
ofHMWtototaladiponectinorHMWtoLMWmayprovide
a better reﬂection of peripheral insulin sensitivity than total
adiponectin alone [50]. Compared with total adiponectin,
HMW adiponectin is recognized as a predictor of risk of
developingtype2diabetesandevenastrongerpredictorthan
totaladiponectin[51].In particular, high HMW adiponectin
concentrations are strongly associated with lower risk of type
2d i a b e t e s[ 52].
Adiponectin is present in BM, with an average concen-
tration of approximately 19ng/mL (range, 4 to 88ng/mL)
[53].Martin etal.reportedthatimmunoreactiveadiponectin
levels in human milk were signiﬁcantly higher than leptin
levels, and that they decreased with the duration of lactation
[54]. Bronsk´ y et al. looked for adipose-tissue-generated
proteins that are related to lipid metabolism in BM and
foundadiponectin,adipocytefattyacid-bindingprotein,and
epidermal fatty acid-binding protein [55].
Interestingly, adiponectin was found to be more abun-
dantin cordblood (30.6mg/L)than in eitherBM (10.9μg/L)
or maternal serum (8.6mg/L) [56], conﬁrming data from
previous observational studies showing that cord blood
adiponectin levels are higher than those seen in adults [57].
Similar cord blood adiponectin levels (28.5μg/mL) were
detectedinarecentstudy,inwhich itwasfoundtobedirectly
associated with birth weight for gestational age, inversely
associated with weight gain in the ﬁrst 6 months of life, and
topredict an increase in central adiposity at theage of 3years
[58].
Given the biological properties of adiponectin, its pres-
ence in BM and the expression of adiponectin receptor 1 in
the small intestine of neonatal mice [59], not only adipose-
tissue-produced adiponectin but also milk adiponectin, may
aﬀect infant growth and development.
3.1. Role of Adiponectin on Glucose Homeostasis and Insulin
Action. Adiponectin is involved in the regulation of glucose
metabolism. In the liver, adiponectin increases insulin action
by suppressing FA inﬂux and increasing fat oxidation,
decreasing gluconeogenesis, and reducing ectopicfat deposi-
tion in the liver [60]. In muscle cells, adiponectin increases
glucose utilization by increasing FA oxidation and thus
decreasing the triglyceride content in skeletal muscle [61].
Adiponectin-linked insulin sensitization is mediated, at least
inpart, byactivationofadenosine monophosphate-activated
protein kinase (AMPK) in skeletal muscles and the liver,
which increases FA oxidation and reduces hepatic glucose
production [62].
Low adiponectin seems to be a cause rather than a
consequence of hyperinsulinaemia. Prospective studies show
that low levels of adiponectin precede a decrease in insulin
sensitivity [63].Insulinmaysuppressadiponectinlevels[64].
Serum adiponectin is decreased in insulin resistance and
type 2 diabetes, independently of adiposity [65]. Genetic
polymorphisms responsible for hypoadiponectinaemia are
associated with insulin resistance [66]. Plasma adiponectin
levels are inversely related to the degree of adiposity; in
fact, obese individuals have decreased plasma adiponectin
concentrations, and females, who are proportionately fatter
than males, show lower adiponectin levels [67]( Table 2).
3.2. Adiponectin and Glucose Homeostasis in Newborns and
Infants. Circulating adiponectin levels correlate negatively
with the degree of adiposity in children aged between 5
and 10 years [68]. In contrast, in full-term neonates, during
the ﬁrst few days of life, serum and plasma adiponectin
levels correlate positively with birth weight and length,
neonatal adiposity, and circulating levels of leptin [69].
Furthermore, adiponectin concentrations in cord blood are
higher than those reported in adolescents and in adults [70].
In preterm infants, serum adiponectin levels are lower than
those in full-term infants, correlate positively with body
weight, and increase with postnatal age, which suggests a
metabolic adaptation to premature extrauterine life [71].
Blood adiponectin levels increase with postnatal age in
premature infants, suggesting a rapid, as yet unexplained,
metabolic adaptation to premature extrauterine life [72].
In prepubertal children who were born SGA, serum
adiponectin levelswere comparable to AGA children [73]. In
another study, the SGA < 3rd percentile children had higher
a d i p o n e c t i nt h a nA G Ac h i l d r e n[ 74].
4.Resistin
The peptide hormone resistin, also called FIZZ3, is an
adipocyte-derived secretory factor which was ﬁrst identiﬁed
as a novel transcript produced exclusively by adipocytes and
has been shown to play a signiﬁcant role in obesity-induced
insulin resistance [7]. The name was considered appropriate
because resistin was reported to antagonize insulin action
in cells in vitro as well in vivo. Resistin is expressed within
adipocytes of rodents [7] and mainly in macrophages of
humans [75], and its production is increased with feeding
and obesity and decreased by PPARγ ligands [76]. It is also
found in serum in mice and in humans [7, 77].
Resistin gene expression has been demonstrated in
human placental tissues, mainly in trophoblastic cells, in
particular in term placental tissue, it is more prominent
than in the ﬁrst trimester chorionic tissue [78]. Ilcol et al.International Journal of Pediatrics 5
investigated if human milk was a possible source of resistin.
They showed that resistin is present in human BM, and its
concentration in BM decreases with time during lactation,
withlevelsranging from1710 ±68pg/mLat1–3postpartum
days to 670 ± 18pg/mL at 91–180 postpartum days [79].
Expression of resistin is low during food deprivation
and increases greatly during refeeding. Resistin plays a role
as a regulator of glucose homeostasis, inhibits adipocyte
diﬀerentiation, and may function as a feedback regulator of
adipogenesis [80].
4.1.RoleofResistinonGlucoseHomeostasisandInsulinAction.
Steppan et al. suggested that resistin is a unique hormone
whose eﬀects on glucose metabolism are antagonistic to
those of insulin [7]. Two independent studies, in which
recombinant resistin was administered to rodents, argue that
resistin can increase blood glucose levels and cause insulin
resistance. Indeed, Rajala et al. showed that in rodents acute
resistin increased glucose production, possibly by activation
of the glucose-6-phosphatase gene and without apparent
changes in glucose utilization by skeletal muscle and adipose
tissue [81]. Administration of resistin to mice resulted
in increased glucose production and blood glucose levels
and impaired insulin action; neutralization of resistin by
injection of antibodies in diet-induced obese mice decreased
blood glucose levels and improved insulin sensitivity [7].
In rat skeletal muscle cells, it has been shown that
resistin does not alter insulin receptor signaling but aﬀects
insulin-stimulated glucose uptake,presumably by decreasing
the intrinsic activity of cell surface glucose transporters
[82]. In mature 3T3-L1 adipocytes, resistin reduces insulin-
stimulated glucose uptake by activating SOCS3, which is
an inhibitor of insulin signaling [83]. These studies suggest
that resistin may contribute to insulin resistance, and its
eﬀects are being mediated at target tissue such as liver,
skeletal muscle, and adipose tissue. Interestingly, it has been
observedthatinsulinseemstoinhibitresistinsecretion,while
resistin induces insulin resistance, in an insulin-resistin-
insulin sensitivity positive feedback loop [84].
The long-term in vivo function of resistin was studied in
mice knockout for resistin gene. In resistin-deﬁcient (R−/−)
mice neither R-mRNA nor resistin protein were expressed
in white adipose tissue, and resistin was not found in R−/−
serum. Blood glucose levels in the R−/− mice, when fed a
high-fatdiet,were20%to30%lowerthaninwild-type(WT)
controls, and glucose production was reduced compared
with WT control [85].
Regulation of resistin expression has been studied in
response to insulin and glucose. Experimental studies
showed that resistin mRNA levels are increased in response
to acute hyperglycaemia and decrease in response to hyper-
insulinaemia in mice [86] and in 3T3-L1 adipocytes [87].
4.2. Resistin in Obesity and Diabetes. Resistin expression has
been analysed in rodent models of obesity and diabetes,
suggesting that it is not clear if serum resistin levels in
obesity genetic models (ob/ob and db/db) as well as in a
diet-induced model of diabetes and obesity are elevated or
decreased[7,86].This ﬁnding suggeststhatresistin mayhave
littleor no contributionto insulin resistance and thatthere is
already conﬂicting evidence in relation to changes in resistin
expression in dietary and genetic models of rodent obesity.
Owecki et al. examined correlations between serum
resistin concentrations and the degree of human obesity
and insulin sensitivity. Obese subjects showed higher resistin
concentrations than nonobese controls, but despite these
diﬀerent concentrations, no relationship between resistin
concentration and insulin resistance has been found [88]. In
obese children serum resistin levels did not diﬀer from that
of control subjects [89].
In a study conducted on patients with type 2 diabetes,
serum resistin concentration was signiﬁcantly higher than in
normal subjects [90]( Table 2).
4.3. Resistin and Glucose Homeostasis in Newborns and
Infants. Cord blood levels of resistin and their postnatal
changes in term AGA neonates have been investigated,
showing high resistin levels at birth (8.63 ± 2.94ng/mL),
similar to those on the 4th day of life (7.87 ± 4.02ng/mL).
These ﬁndings suggest that this hormone may play a role
in maintenance of metabolic neonatal homeostasis [91]. In
a sample of 37 neonates born at term mean, umbilical serum
resistin concentration was 21.34 ± 1.07ng/mL, ranging
from 10.61 to 40.81ng/mL [92]. Moreover, plasma resistin
concentrations were signiﬁcantly higher in term (12.1;
range: 7.8–17.7ng/mL) than in preterm infants (5.2; range:
3.4–12.7ng/mL), suggesting that high circulating resistin
levels at term gestation could be advantageous to the infant
by promoting hepatic glucose production and preventing
hypoglycemia after birth [93]. In term newborns of mothers
with insulin-dependent diabetes, serum resistin is signiﬁ-
cantly suppressed, suggesting that the metabolic hormonal
system is probably operational in fetal and early postnatal
life. The suppressive eﬀectof insulin on resistin may partially
explaintheexcessaccumulationofadiposetissueininfantsof
diabetic mothers by reducing the inhibitory eﬀect of resistin
on adipogenesis [94].
5.Ghrelin
Ghrelin was identiﬁed as an endogenous ligand for the
growth hormone secretagogue receptor type 1a (GHS-R 1a)
[95]. It is a peptide hormone of 28 amino acids with an
octanoyl group on the serine in position 3, which is crucial
for its biological activity [96]. GHS-R 1a is expressed mainly
in the pituitary and hypothalamus. Ghrelin is produced pre-
dominantly by the stomach, by the X/A-like endocrine cells,
and by many other tissues such as pituitary, hypothalamus,
bowel,lung,heart,pancreas, kidney,placenta,andtestis[97].
As suggested by its widespread distribution, ghrelin has a
widespectrumofbiologicalactivitiesbeyondthestimulation
ofgrowthhormonerelease[98,99].Indeed,ghrelin regulates
gastric motility, acid secretion, pancreatic secretion, glucose
and lipid metabolism, and cell proliferation and exerts
cardiovascular and anti-inﬂammatory eﬀects [100, 101].
Ghrelin has a short-term action on energy homeostasis,
stimulating appetite and food intake, and a long-term
eﬀect, enhancing fat-mass deposition and body-weight gain6 International Journal of Pediatrics
[102]. Ghrelin secretion is increased by fasting and in
response to weight loss, while it decreases under positive
energy-balance conditions, such as food intake and obesity
[103].
Ghrelin is present in both term and preterm human
BM; its levels are higher in whole milk than in skim milk,
with median ghrelin level in whole BM of 2125pg/mL
[104].Aydinetal. showed lowerconcentrationsincolostrum
(70.3 ± 18pg/mL), transitional milk (83.8 ± 18pg/mL),
and mature milk (97.3 ± 13pg/mL) [105]. Acylated ghrelin
has also been reported in BM; its concentrations increase
during lactation and are signiﬁcantly related to serum
ghrelin concentrations in BF infants; active and total ghrelin
concentrations in BM were lowest (450 ± 25 and 880
± 80pg/mL, resp.) at 0–3 days, whereas they increased
progressively during 180 days of lactation period to 801
± 43 and 3250 ± 380pg/mL at 91–180 days postpartum
[106].
5.1.RoleofGhrelinonGlucoseHomeostasisandInsulin Action.
There are contrasting reports concerning the inﬂuence of
ghrelin on insulin secretion. Earlier experiments observed
that ghrelin stimulates the release of insulin in isolated
rat pancreatic islets [107]. Subsequently, ghrelin has been
shown to inhibit insulin secretion in rat pancreatic β cells
in vitro [108], and this eﬀect has been conﬁrmed also in
studies in vivo in several species [109]. In agreement with
the assumption that ghrelin negatively modulates pancreatic
β-cell secretion, recently it has been demonstrated that in
humans ghrelin induces a signiﬁcant increase in plasma
glucose levels that is followed, surprisingly, by a reduction
in insulin secretion [110]. Studies in vitro have shown that
ghrelin inhibits insulin eﬀects, inhibiting glycogen synthesis
and promoting gluconeogenesis [111]. Studies in human
subjects found that administration of ghrelin induces hyper-
glycaemia and reduces insulin secretion, probably through a
directglycogenolyticeﬀect[112].Also,ghrelin secretion may
besuppressed,atleastinpart,byanincreased plasmaglucose
level as well as by insulin, as shown by hyperinsulinemic
euglycemic clamp studies in healthy subjects [113]. These
ﬁndings indicate that insulin is a physiological and dynamic
modulator of plasma ghrelin and that insulinemia possibly
mediates the eﬀect of nutritional status on its concentration.
Changes in plasma ghrelin concentrations have been
reportedinanimal modelsofdiabetesandinhumandiabetes
type 1 and type 2. It has been shown in a model of
streptozotocin-induced diabetes that plasma ghrelin concen-
tration and preproghrelin mRNA expression in the stomach
of the diabetic rats increased signiﬁcantly whereas their gas-
tric ghrelin level and the number of ghrelin-immunoreactive
cells in the gastric fundus decreased signiﬁcantly [114]. In
type 1 diabetic patients decreased plasma ghrelin levels have
been documented [115–117], and after prolonged insulin
treatment or food intake, a suppression of plasma ghrelin in
these patients has been shown [118, 119]. Also in children
with insulin-treated type 1 diabetes, the plasma ghrelin
levels were found to be lower than those measured in
controls with a negative association of their plasma ghrelin
levels with daily insulin dosage [116]. Further low levels of
plasma ghrelin persisted during long-term insulin treatment
[120].
The relationship between plasma ghrelin concentration
and serum insulin level or insulin resistance in patients
with type 2 diabetes is still controversial, even though a
large number of studies indicated decreased plasma ghrelin
levels in obese type 2 diabetic patients [121–124]. Moreover,
a negative correlation between fasting plasma ghrelin and
insulin was observed, suggesting that hyperinsulinaemia
associated with insulin resistance may be an important
determinant of decreased plasma ghrelin levels in patients
with type 2 diabetes [125].
Althoughdecreased plasma ghrelin levelsmay contribute
to either the development of hyperinsulinaemia or to the
restraint of weight gain in patients with type 2 diabetes,
the lack of data about the cause-and-eﬀect relationship
makes it diﬃcult to propose an exact role of ghrelin in
the development of type 2 diabetes. It seems possible that
decreased plasma ghrelin concentrations in type 2 diabetic
patients may be due to a compensatory mechanism against
diminished insulin action or against hyperglycaemia [126]
(Table 2).
5.2. Ghrelin and Glucose Homeostasis in Newborns and
Infants. Ghrelin has been detected in cord plasma as early
as 30 weeks of gestation, suggesting a possible role in fetus
developing [127].
In newborns, cord blood ghrelin levels are higher in
preterm SGA babies (602ng/L; 95% CI: 330–1211) than in
preterm AGA ones (200ng/L; 95% CI:164–245). Reduced
ghrelin suppression and higher postprandial ghrelin levels
in SGA infants could result in a sustained orexigenic drive
andcouldcontributetopostprandialcatchupgrowthinthese
infants [128].
Also preterm newborns SGA show higher cord blood
g h r e l i nl e v e l st h a nA G Ao n e s[ 129], and newborns who had
intrauterine growth restriction show low cord blood glucose
concentrations and increased ghrelin concentrations [130].
It has been observed that the rate of weight gain over the
ﬁrst year inSGA infants correlate with a variable suppression
of circulating ghrelin levels. In fact, SGA infants who showed
poor catchup growth showed a larger decline in ghrelin
concentrations measured during fasting and 10 minutes
after intravenous (iv) glucose. Higher ghrelin levels or lower
reductionsin circulatinglevelsfollowing iv glucosewere seen
in SGA infants who showed greater infancy weight gain,
suggesting that sustained orexigenic drive could contribute
to postnatal catchup growth [131].
Studies on serum ghrelin levels in infants are scanty. In
a study conducted on infants in the ﬁrst 4 months of life,
FF infants showed higher serum ghrelin levels compared to
BF ones [132]. In a cohort of infants aged until 18 months,
serum ghrelin correlated positively with fasting time, and a
negative inﬂuence of insulin on ghrelin levels was observed
[133]. A positive correlation between circulating ghrelin
levels and fasting time was observed also in exclusively FF
infants in the ﬁrst 6 months of life [134].International Journal of Pediatrics 7
6.Conclusions
Consistent evidence suggests that the complex mechanisms
implicated in energy homeostasis involve the central ner-
vous system and peripheral organs, connecting each other
food intake, energy expenditure, and glucose homeostasis.
Moreover, it seems that early-life nutrition and growth could
program the set point of energy homeostasis later in life.
Several hormones, such as leptin, adiponectin, resistin and
ghrelin are involved in this complex regulation, and their
presence in BM has been demonstrated, representing the
linkbetweenbreastfeedingandprotectionagainstmetabolic-
related disorders in later life. In fact, these hormones may
be involved in the regulation of growth and development
in the neonatal age and in infancy and could take part
in the programming of energy balance in childhood and
adulthood, and they may be implicated in the development
of obesity, diabetes, and metabolic syndrome.
Considering leptin, studies in animals and humans
show that it plays a pivotal role in the regulation of
glucose homeostasis. Leptin is implicated in the regulation
of food intake and energy homeostasis in early life, when
this hormone also controls fetal growth and development;
particularly in neonatal period, it is also an essential factor
for the development of hypothalamic pathways involved in
the regulation of energy balance.
Also adiponectin is involved in the regulation of glucose
metabolism, increasing insulin action in liver and rising
glucose utilization in skeletal muscle. This hormone plays
a role since early life, and its serum levels correlate with
neonatal growth parameters, adiposity, and circulating levels
of leptin.
As concernsresistin, itis a uniquehormone whose eﬀects
on glucose metabolism are antagonistic to those of insulin.
Particularly, insulin seems to inhibit resistin secretion, while
resistin induces insulin resistance, in an insulin-resistin-
insulin sensitivity positive feedback loop. This hormone
may play a role in maintenance of metabolic neonatal
homeostasis; high circulating resistin levels at term gestation
could be advantageous to the infant by promoting hepatic
glucoseproduction and preventing hypoglycemia after birth.
Ghrelin induces a signiﬁcant increase in plasma glucose
levels that is followed, surprisingly, by a reduction in insulin
secretion. Also ghrelin has possible role in early life growth
and development, as it has been detected in cord plasma
since 30 weeks of gestation, and its serum levels correlate
with growth parameters in neonates and infants, sustaining
an orexigenic drive and contributing to catchup growth.
Data on bioavailability and metabolic eﬀects of oral
administration of these hormones are scanty as compared
to hormones previously discovered such as insulin, GH, or
thyroid hormone; in particular, eﬀects of leptin or ghrelin
administration are documented as reported above, while
data about the other hormones are still limited.
Longitudinal investigations will shed light on the new
hormones discovered in mother’s milk and their potential
protective eﬀect on subsequent obesity and metabolic-
related disorders, in particular in the control of glucose
homeostasis.
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